Analytical Data
-
Gene name
SIAH2
- Application
-
Alternative Names
E3 ubiquitin-protein ligase Siah2; hSiah2; Seven in absentia homolog 2; Siah E3 ubiquitin protein ligase 2; Siah-2; siah2; SIAH2_HUMAN; Ubiquitin Ligase Siah2
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O43255
-
Expression Region
1-324 aa
-
AA Sequence
MSRPSSTGPS ANKPCSKQPP PQPQHTPSPA APPAAATISA AGPGSSAVPA AAAVISGPGG GGGAGPVSPQ HHELTSLFEC PVCFDYVLPP ILQCQAGHLV CNQCRQKLSC CPTCRGALTP SIRNLAMEKV ASAVLFPCKY ATTGCSLTLH HTEKPEHEDI CEYRPYSCPC PGASCKWQGS LEAVMSHLMH AHKSITTLQG EDIVFLATDI NLPGAVDWVM MQSCFGHHFM LVLEKQEKYE GHQQFFAIVL LIGTRKQAEN FAYRLELNGN RRRLTWEATP RSIHDGVAAA IMNSDCLVFD TAIAHLFADN GNLGINVTIS TCCP
-
Molecular Weight
34.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SIAH2 (Siah E3 Ubiquitin Ligase 2) is a member of the Siah family of E3 ubiquitin ligases, which play critical roles in regulating protein degradation through the ubiquitin-proteasome pathway. Research on SIAH2 has gained significant attention due to its involvement in various cellular processes, including apoptosis, cell cycle regulation, and transcriptional control. Aberrant expression of SIAH2 has been implicated in numerous pathological conditions, particularly cancer, where it can influence tumor progression and response to therapy by modulating the stability of key oncogenic and tumor suppressor proteins. The study of SIAH2 is further complicated by its ability to form complexes with other proteins and its regulation by oxygen levels, linking it to hypoxic responses and oxidative stress. As a result, researchers are keenly interested in understanding the molecular mechanisms by which SIAH2 exerts its effects in normal physiology and disease states. Recombinant SIAH2 proteins are essential for elucidating its biochemical properties and interactions, and for exploring potential therapeutic strategies targeting this ubiquitin ligase in cancer and other diseases. By investigating SIAH2, scientists aim to uncover new insights into cellular signaling pathways and develop novel interventions to combat malignancies characterized by dysregulated SIAH2 activity. Through such studies, the potential of SIAH2 as a biomarker or therapeutic target is being evaluated, which may lead to improved diagnostic and treatment options for patients with various cancers.
